SCHEMBL10072022

SCHEMBL10072022

Cc1ccc(CCc2cc3c(cn2)cc(-c2cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc2C)c(=O)n3C)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.62
MAPK14 Q16539 5/20 0.50
LCK P06239 5/20 0.50
KDR P35968 4/20 0.50
JAK3 P52333 2/20 0.50
TEK Q02763 1/20 0.50
RAF1 P04049 11/20 0.49
BRAF P15056 11/20 0.49
DDR2 Q16832 1/20 0.49
BTK Q06187 2/20 0.47
ABL1 P00519 2/20 0.47
KIT P10721 2/20 0.47
MAPK13 O15264 1/20 0.47
LYN P07948 1/20 0.47
PDGFRA P16234 1/20 0.47
MAPK12 P53778 1/20 0.47
EPHB4 P54760 1/20 0.47
EPHA4 P54764 1/20 0.47
MAPK11 Q15759 1/20 0.47
SRC P12931 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043799 0.97 SYK (0.62) SYKMAPK14LCKKDRJAK3
SCHEMBL10043790 0.96 SYK (0.61) SYKMAPK14LCKKDRJAK3
SCHEMBL10044001 0.94 SYK (0.61) SYKMAPK14LCKKDRJAK3
SCHEMBL10043997 0.92 SYK (0.65) SYKMAPK14LCKKDRJAK3
SCHEMBL502335 0.92 SYK (0.65) SYKMAPK14LCKKDRJAK3
SCHEMBL10043793 0.91 SYK (0.65) SYKMAPK14LCKKDRJAK3
SCHEMBL10043995 0.91 SYK (0.64) SYKMAPK14LCKKDRJAK3
SCHEMBL10044009 0.91 SYK (0.59) SYKMAPK14LCKKDRJAK3
SCHEMBL10072197 0.90 SYK (0.67) SYKMAPK14LCKKDRJAK3
SCHEMBL10044004 0.90 SYK (0.61) SYKMAPK14LCKKDRJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885MAPK14 117/4885LCK 4/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885MAPK14 117/4885LCK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.